Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2009

Primary Completion Date

February 28, 2011

Conditions
Bladder Cancer
Interventions
DRUG

BCG and CP-675,206

"Dose level -1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 3 mg/kg I.V. week 3, week 15~Dose level 1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 6 mg/kg I.V. week 3, week 15~Dose level 2: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 10 mg/kg IV week 3, week 15~Dose level 3: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 15 mg/kg IV week 3, week 15"

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University of Wisconsin, Madison

OTHER

NCT00880854 - Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer | Biotech Hunter | Biotech Hunter